Literature DB >> 32789350

Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36.

Amarasooriya M D S Jayawardhana1, Morgan Stilgenbauer, Payel Datta, Zihan Qiu, Sarine Mckenzie, Han Wang, David Bowers, Manabu Kurokawa, Yao-Rong Zheng.   

Abstract

Resistance to the platinum-based chemotherapy drug, cisplatin, is a significant setback in ovarian cancer. We engineered fatty acid-like Pt(iv) prodrugs that harness the fatty acid transporter CD36 to facilitate their entry to ovarian cancer cells. We show that these novel constructs effectively kill cisplatin-resistant ovarian cancer cells.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32789350     DOI： 10.1039/d0cc02174a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  3 in total

1.  Interactions between mitochondria-damaging platinum(IV) prodrugs and cytochrome c.

Authors:  Amarasooriya M D S Jayawardhana; Yao-Rong Zheng
Journal:  Dalton Trans       Date:  2022-02-01       Impact factor: 4.390

2.  Upregulation of CD36, a Fatty Acid Translocase, Promotes Colorectal Cancer Metastasis by Increasing MMP28 and Decreasing E-Cadherin Expression.

Authors:  James Drury; Piotr G Rychahou; Courtney O Kelson; Mariah E Geisen; Yuanyuan Wu; Daheng He; Chi Wang; Eun Y Lee; B Mark Evers; Yekaterina Y Zaytseva
Journal:  Cancers (Basel)       Date:  2022-01-05       Impact factor: 6.639

Review 3.  Fatty Acid Metabolism in Ovarian Cancer: Therapeutic Implications.

Authors:  Hyunho Yoon; Sanghoon Lee
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.